Regulatory

CIRS RD Briefing 74 – OpERA programme

CIRS has collected regulatory assessment data for over 20 years, initially with ICH and ICH-observing countries. The OpERA programme, “Optimising Efficiencies in Regulatory Agencies (OpERA)”, was initiated through CIRS [...]

2021-06-07T10:56:57+00:00January 8th, 2020|Tags: , |

Keyter et al 2019 – Evaluation of the performance of the South African regulatory agency

Background: Timely access to new medicines may be addressed through strengthening of registration efciencies and timelines by establishing and refning value-added registration processes, resources, and systems. The aims of [...]

2021-01-18T17:15:51+00:00December 12th, 2019|Tags: , , |

Kühler et al 2019 – To what degree are review outcomes aligned for new active substances between the EMA and the US FDA?

Objective To compare review outcome alignment between European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for medicines approved by both agencies in the time period 2014–2016. Design [...]

2021-01-18T17:13:15+00:00November 15th, 2019|Tags: , |

Project report – Monitoring implementation and adherence to ICH guidelines

Background: According to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Articles of Association, the regulatory members of ICH are expected to implement [...]

2023-11-22T14:40:38+00:00November 1st, 2019|Tags: , |

Executive Colloquium report – What is the value and return on investment for our company to maintain a regulatory policy function?

In June 2019, the Centre for Innovation in Regulatory Science (CIRS) held an Executive Colloquium in Rockville, MD, USA that brought together representatives from multinational pharmaceutical companies to gauge [...]

2021-01-19T11:11:41+00:00October 17th, 2019|Tags: |

CIRS RD Briefing 71 – Trends in the regulatory landscape Latin America

To address the complex challenges in the global regulatory environment and the growing demand for patient access to new medicines, regulatory agencies in Latin America are actively engaging in regulatorystrengthening [...]

2021-01-19T11:05:26+00:00July 9th, 2019|Tags: , |

CIRS RD Briefing 72 – Trends in the regulatory landscape Asia

To address the complex challenges in the global regulatory environment and the growing demand for patient access to new medicines, regulatory agencies in Asia are actively engaging in regulatory-strengthening and [...]

2021-01-19T11:06:53+00:00July 9th, 2019|Tags: |

CIRS RD Briefing 70 – New approvals in six regulatory authorities 2009-18

Major improvements in the regulatory environment as well as changes in strategies of multinational companies have led to a general decrease in the time to marketing authorisation and improved consistency [...]

2021-01-19T11:08:18+00:00May 13th, 2019|Tags: , |

Keyter et al 2019 – South African Medicines Control Council: Comparison of Its Registration Process

Introduction: Comparisons between regulatory authorities of similar size and regulatory characteristics facilitate value-added benchmarking and provide insight into regulatory performance. Such comparisons highlight areas for improvement as authorities move [...]

2021-01-18T17:08:49+00:00March 14th, 2019|Tags: , , |
Go to Top